<DOC>
	<DOCNO>NCT00163761</DOCNO>
	<brief_summary>This Phase II trial evaluate efficacy ( overall response rate ) risk-adjusted outpatient base approach lymphoma salvage therapy vinorelbine , gemcitabine pegfilgrastim and/or gemcitabine , ifosfamide , vinorelbine pegfilgrastim .</brief_summary>
	<brief_title>Efficacy Study Outpatient Therapy Lymphoma</brief_title>
	<detailed_description>Lymphoma increase incidence annually past several decade majority patient relapse first line therapy . A variety 'salvage chemotherapy ' treatment available usually inpatient-based treatment associate significant haematological toxicity . Furthermore , patient treat manner despite fact patient well irrespective type salvage therapy whereas others badly matter do . During 2001-2002 undertook pilot study 40 patient use outpatient-based salvage therapy 2 new chemotherapy drug , vinorelbine gemcitabine . Over 75 % treatment successfully deliver outpatient basis response rate similar historical control . We propose expand initial finding modify outpatient approach patient less favourable prognostic feature , , patient stratify differ therapy majority still receive proven vinorelbine-gemcitabine combination .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>age &gt; 18 year relapse primary refractory nonHodgkin 's lymphoma ( NHL ) Hodgkin 's Disease ( HD ) ECOG 0 2 write informed consent Exclusion criterion : Intention proceed form transplant therapy follow few 2 cycle protocol salvage therapy bilirubin &gt; 50Î¼mol/litre unless secondary lymphoma creatinine &gt; 2 x upper limit normal unless secondary lymphoma , absolute neutrophil count &lt; 0.5 x 109/litre / platelet &lt; 50 x 109/litre unless secondary lymphoma relapse within 6 month prior transplant procedure ( autologous allogeneic ) know sensitivity E coli derive preparation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Lymphoma</keyword>
</DOC>